Article info

Download PDFPDF

Original research
Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab and tofacitinib monotherapies in rheumatoid arthritis patients who are naïve to treatment with biologic or conventional synthetic disease-modifying antirheumatic drugs: a matching-adjusted indirect comparison

Authors

  1. Correspondence to Dr Bruno Fautrel; bruno.fautrel{at}aphp.fr
View Full Text

Citation

Fautrel B, Zhu B, Taylor PC, et al
Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab and tofacitinib monotherapies in rheumatoid arthritis patients who are naïve to treatment with biologic or conventional synthetic disease-modifying antirheumatic drugs: a matching-adjusted indirect comparison

Publication history

  • Received October 24, 2019
  • Revision received February 29, 2020
  • Accepted March 2, 2020
  • First published May 5, 2020.
Online issue publication 
May 05, 2020

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.